ARTÍCULO

MMP10 promotes efficient thrombolysis after ischemic stroke in mice with induced diabetes

Autores: Navarro Oviedo, Manuel; Roncal Mancho, Carmen; Salicio Castillo, Agustina; Belzunce Saldise, Miriam; Rabal, O.; Toledo Atucha, Estefanía Ainhoa; Zandio, B.; Rodríguez García, José Antonio; Páramo Fernández, José Antonio; Munoz, R.; Orbe Lopategui, Josune (Autor de correspondencia)
Título de la revista: TRANSLATIONAL STROKE RESEARCH
ISSN: 1868-4483
Volumen: 10
Número: 4
Páginas: 389 - 401
Fecha de publicación: 2019
Lugar: WOS
Resumen:
Diabetes is an important risk factor for ischemic stroke (IS). Tissue-type plasminogen activator (tPA) has been associated with less successful revascularization and poor functional outcome in diabetes. We assessed whether a new thrombolytic strategy based on MMP10 was more effective than tPA in a murine IS model of streptozotocin (STZ)-induced diabetes. Wild-type mice were administered a single dose of streptozotocin (STZ) (180mg/kg) to develop STZ-induced diabetes mellitus. Two weeks later, IS was induced by thrombin injection into the middle cerebral artery and the effect of recombinant MMP10 (6.5 mu g/kg), tPA (10mg/kg) or tPA/MMP10 on brain damage and functional outcome were analysed. Motor activity was assessed using the open field test. Additionally, we studied plasminogen activator inhibitor-1 (PAI-1) and thrombin-antithrombin complex levels (TAT) by ELISA and oxidative stress and blood-brain barrier (BBB) integrity by immunohistochemistry and western blot. MMP10 treatment was more effective at reducing infarct size and neurodegeneration than tPA 24h and 3days after IS in diabetic mice. Locomotor activity was impaired by hyperglycemia and ischemic injury, but not by the thrombolytic treatments. Additionally, TAT, oxidative stress and BBB permeability were reduced by MMP10 treatment, whereas brain bleeding or PAI-1 expression did not differ between treatments. Thrombolytic treatment with MMP10 was more effective than tPA at reducing stroke and neurodegeneration in a diabetic murine model of IS, without increasing haemorrhage. Thus, we propose MMP10 as a potential candidate for the clinical treatment of IS in diabetic patients.